Patterns and determinants of statin prescribing and discontinuation in individuals aged 80 and older: A 10-year population-based cohort study

IF 2.5 4区 医学 Q3 PHARMACOLOGY & PHARMACY
Myriam Khelifi, Marc Simard, Véronique Boiteau, Marie-Eve Gagnon, Olivia Dalleur, Caroline Sirois
{"title":"Patterns and determinants of statin prescribing and discontinuation in individuals aged 80 and older: A 10-year population-based cohort study","authors":"Myriam Khelifi,&nbsp;Marc Simard,&nbsp;Véronique Boiteau,&nbsp;Marie-Eve Gagnon,&nbsp;Olivia Dalleur,&nbsp;Caroline Sirois","doi":"10.1016/j.japh.2025.102445","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Considering the limited knowledge regarding the benefits and risks of statins in people ≥80 years, population use patterns can provide valuable insights.</div></div><div><h3>Objective</h3><div>To describe prescribing and discontinuation patterns for statins, along with their determinants, in people ≥80 years in Québec, Canada.</div></div><div><h3>Methods</h3><div>Using the Quebec Integrated Chronic Disease Surveillance System, we built a population-based cohort of community-dwelling adults aged ≥80 years on January 4, 2018. We assessed statin use in the 5 years before and after cohort entry to calculate the proportion of prevalent, incident, and discontinued statin users. We used multivariable Cox models to identify factors associated with initiation and discontinuation, using hazard ratios (HRs) and 95% confidence intervals.</div></div><div><h3>Results</h3><div>A total of 317,027 individuals of mean age 85.2 years were included. At cohort entry, 51% were prevalent statin users. Within 5 years, 11% of nonusers initiated a statin. Among prevalent users, 22% discontinued their therapy during follow-up. Strongest factors associated with initiation included ages 80–84 (HRs ranging from 0.74 [95% confidence interval: 0.71–0.76] for 85–89 years to 0.26 [0.22–0.30] for 95+), previous statin use (1.99 [1.93–2.07]), and male sex (1.44 [1.39–1.49]). Older age (HRs ranging from 1.54 [1.51–1.58] for 85–89 years to 3.65 [3.42–3.89] for 95+), and Alzheimer's disease (1.77 [1.71–1.82]) were the most common factors for discontinuation. Previous cardiovascular disease was associated with both initiation (1.26 [1.07–1.49]) and reduced likelihood of discontinuation (0.69 [0.64–0.74]).</div></div><div><h3>Conclusion</h3><div>Statin use remains prevalent among the ≥80 years. A thorough evaluation of the risk/benefit balance of such use is needed.</div></div>","PeriodicalId":50015,"journal":{"name":"Journal of the American Pharmacists Association","volume":"65 5","pages":"Article 102445"},"PeriodicalIF":2.5000,"publicationDate":"2025-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the American Pharmacists Association","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1544319125001244","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Considering the limited knowledge regarding the benefits and risks of statins in people ≥80 years, population use patterns can provide valuable insights.

Objective

To describe prescribing and discontinuation patterns for statins, along with their determinants, in people ≥80 years in Québec, Canada.

Methods

Using the Quebec Integrated Chronic Disease Surveillance System, we built a population-based cohort of community-dwelling adults aged ≥80 years on January 4, 2018. We assessed statin use in the 5 years before and after cohort entry to calculate the proportion of prevalent, incident, and discontinued statin users. We used multivariable Cox models to identify factors associated with initiation and discontinuation, using hazard ratios (HRs) and 95% confidence intervals.

Results

A total of 317,027 individuals of mean age 85.2 years were included. At cohort entry, 51% were prevalent statin users. Within 5 years, 11% of nonusers initiated a statin. Among prevalent users, 22% discontinued their therapy during follow-up. Strongest factors associated with initiation included ages 80–84 (HRs ranging from 0.74 [95% confidence interval: 0.71–0.76] for 85–89 years to 0.26 [0.22–0.30] for 95+), previous statin use (1.99 [1.93–2.07]), and male sex (1.44 [1.39–1.49]). Older age (HRs ranging from 1.54 [1.51–1.58] for 85–89 years to 3.65 [3.42–3.89] for 95+), and Alzheimer's disease (1.77 [1.71–1.82]) were the most common factors for discontinuation. Previous cardiovascular disease was associated with both initiation (1.26 [1.07–1.49]) and reduced likelihood of discontinuation (0.69 [0.64–0.74]).

Conclusion

Statin use remains prevalent among the ≥80 years. A thorough evaluation of the risk/benefit balance of such use is needed.
80岁及以上人群他汀类药物处方和停药的模式和决定因素:一项为期十年的基于人群的队列研究。
背景:考虑到关于他汀类药物在≥80岁人群中的获益和风险的知识有限,人群使用模式可以提供有价值的见解。目的:描述他汀类药物的处方和停药模式,以及它们的决定因素,在加拿大quamezbec≥80岁的人群中。方法:利用魁北克慢性疾病综合监测系统,于2018年4月1日建立了一个以人群为基础的队列,研究对象为≥80岁的社区居住成年人。我们评估了队列进入前后5年的他汀类药物使用情况,以计算流行、意外和停止使用他汀类药物的比例。我们使用多变量Cox模型,使用风险比(HR)和95%置信区间(95% CI)来确定与起始和停药相关的因素。结果:共纳入317027例,平均年龄85.2岁。在队列开始时,51%是他汀类药物的普遍使用者。在五年内,11%的非使用者开始服用他汀类药物。在流行的使用者中,22%在随访期间停止了治疗。与起始相关的最强因素包括年龄80-84岁(hr范围从85-89岁的0.74 [95% CI: 0.71-0.76]到95岁以上的0.26[0.22-0.30]),既往使用他汀类药物(1.99[1.93-2.07])和男性(1.44[1.39-1.49])。年龄较大(85-89岁的hr为1.54[1.51-1.58],95岁以上的hr为3.65[3.42-3.89])和阿尔茨海默病(1.77[1.71-1.82])是最常见的停药因素。既往心血管疾病与起始(1.26[1.07-1.49])和停药可能性降低(0.69[0.64-0.74])相关。结论:他汀类药物的使用在≥80岁的人群中仍然普遍。需要对这种使用的风险/利益平衡进行彻底的评价。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
3.30
自引率
14.30%
发文量
336
审稿时长
46 days
期刊介绍: The Journal of the American Pharmacists Association is the official peer-reviewed journal of the American Pharmacists Association (APhA), providing information on pharmaceutical care, drug therapy, diseases and other health issues, trends in pharmacy practice and therapeutics, informed opinion, and original research. JAPhA publishes original research, reviews, experiences, and opinion articles that link science to contemporary pharmacy practice to improve patient care.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信